- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02853994
Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice
July 29, 2016 updated by: MINVASYS
Assessment of Safety and Efficacy of the DEVOIR Sirolimus-Coated Balloon for the Treatment of Native Coronary Artery Lesions in the Real-world Clinical Practice
The study is a prospective, non-randomized, multicenter, post-marketing surveillance study evaluating the CE-marked DEVOIR Sirolimus-Coated Coronary Balloon in 4 subgroups regarding device approved indications:
- In-stent restenosis lesions: either bare metal or drug eluting stent restenosis
- Bifurcation lesions (with drug-eluting stent in main branch and drug-coated balloon in side branch): treatment of lesion of all Medina types except (0,0,1) in native coronary arteries
- Small vessels: treatment of lesions ≤2.75 mm
- BMS implantation followed by DCB inflation
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
500
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with coronary artery diseases (in-stent restenosis, small vessel diseases, bifurcation lesions, de novo lesions)
Description
Patient's inclusion and exclusion criteria are per device instructions for use's indications and contraindications.
Inclusion criteria:
- Patient is at least 18 years old
- Lesion lengths ranging from 8 to 38 mm and diameters ranging from 1.50 mm to 4.00 mm.
Exclusion criteria:
- Patients with a hypersensitivity to Sirolimus drug or its structural activity related compounds.
- Patients with a known hypersensitivity to excipients with phospholipid or related origins.
- Patients whose diseased segment cannot be pre-dilated or prepared before drug coated balloon treatment.
- Severely calcified lesions requiring treatment of other type for e.g. Rotational Atherectomy (Rotablator)
- Patients judged to have lesion that prevents complete inflation of angioplasty balloon or proper placement of delivery catheter
- Patients who cannot receive recommended antiplatelet or anticoagulation therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of Major Adverse Cardiac Events (MACE)
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of Target Lesion Revascularization (TLR)
Time Frame: 12 months
|
12 months
|
Rate of Target Vessel Failure (TVF)
Time Frame: 12 months
|
12 months
|
Rate of Target Vessel Revascularization (TVR)
Time Frame: 12 months
|
12 months
|
Angiographic success
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2016
Primary Completion (ANTICIPATED)
September 1, 2018
Study Completion (ANTICIPATED)
September 1, 2018
Study Registration Dates
First Submitted
July 18, 2016
First Submitted That Met QC Criteria
July 29, 2016
First Posted (ESTIMATE)
August 3, 2016
Study Record Updates
Last Update Posted (ESTIMATE)
August 3, 2016
Last Update Submitted That Met QC Criteria
July 29, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- P1601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CAD
-
Abbott Medical DevicesCompleted
-
Henry Ford Health SystemCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Philips Clinical & Medical Affairs GlobalRecruitingCAD | PAD | DVTUnited States
-
Assiut UniversityNot yet recruitingCABG | CAD | LIMA
-
Brigham and Women's HospitalCompletedKnown CAD, or Intermediate-high Pretest Likelihood for CADUnited States, Canada
-
Ain Shams UniversityNot yet recruiting
-
Boston Scientific CorporationTerminated
-
Mayo ClinicCompleted
-
Ahmad ElheenyCompletedRestoration of Primary Molars With CAD/CAM CrownsEgypt